explore -WSS

explore

author：leisure time 2025-09-30 00:50:15 - browse：994

Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourlais, unfortunately, the worst.

My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps, financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis. Bourla is the man at the top, so the responsibility lies with him.

Pfizer shares have fallen 50% this year to their lowest level in more than a decade, erasing nearly $140 billion in market value. In 2022, the company delivered $100 billion in revenue, boosted by a widely used Covid vaccine and Covid treatment. This year, Covid product sales evaporated — and will fall further next year — leaving a vacuum Pfizer is struggling to fill with aging medicines nearing the end of their patent lives, and newer drugs and vaccines that have not performed as expected.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Crinetics acromegaly drug succeeds in late

entertainment

WSS

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

'Make People Better': The CRISPR babies story you probably don't know

In same hospitals, Black patients receive fewer opioids than white patients

NIH trials fail to test meaningful long Covid therapies, experts say

Naloxone nonprofit donates 200,000 doses after FDA approval

Advances in CAR

leisure time

explore

entertainment

How to save PrEP access — and even expand it

Drastic changes should bring profitability, startup health insurers say

Sports medicine is finally prioritizing gender equality

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Malaria cases in Florida and Texas: Here’s what you need to know

How generative AI is inspiring dreams of a health data revolution

Walensky prepares to leave CDC — and Congress — behind

Methadone doses haven’t kept up in the age of fentanyl

Sports medicine is finally prioritizing gender equality

What drug price negotiations mean for Medicare Part D

hotspot

Drastic changes should bring profitability, startup health insurers say

Advances in CAR

Illumina names Agilent executive as new CEO

Why Novartis is changing the name of its research labs

How generative AI is inspiring dreams of a health data revolution

A rare thyroid diagnosis led to unexpected, all

knowledge

entertainment

focus

hotspot